What FDA’s record states
| Field | What FDA’s record states | Source |
|---|---|---|
| Recipient | Veronvy | FDA letter ↗ |
| Location | Rancho Dominguez, CA | FDA letter ↗ |
| Letter date | Dec 10, 2024 | FDA letter ↗ |
| Posted by FDA | Dec 17, 2024 | FDA index ↗ |
| Issuing office | Center for Drug Evaluation and Research (CDER) | FDA letter ↗ |
| Subject | Unapproved New Drugs/Misbranded | FDA letter ↗ |
| MARCS-CMS number | 694688 | FDA letter ↗ |
| GLP-1 drugs named | GLP-1 (named in the letter, no specific drug) | FDA letter ↗ |
| Response letter | Not published by FDA | FDA letter ↗ |
| Closeout letter | Not published by FDA | FDA letter ↗ |
“Examples of claims observed on your website that establish the intended use of your products as drugs intended for human use include, but may not be limited to, the following: Elily Veronvy and Elily Veronvy 40+ From your webpage https://www.veronvy.com/products/veronvy: • “Veronvy Metabolic Boost Drops successfully helped people lose up to 52 pounds in 3 months during clinical trials and was approved by the Food and Drug Administration last year.” • “Metabolism boost drops for weight management.” • “The Science of GLP-1 . . .”FDA warning letter to Veronvy, Dec 10, 2024 · read the full letter on fda.gov ↗
What this is and is not.A warning letter is FDA’s statement of what it considers significant violations. It is an allegation, not a court finding, and the firm can respond. A closeout letter is posted when FDA confirms the violations were corrected.
Other GLP-1 letters FDA issued that week
Source
Every field above is copied from FDA’s page for this letter, read Oct 3, 2026. The letter on fda.gov ↗ · All 161 GLP-1 warning letters